DAILY PROGRAM

Standard Time: GMT +09:00, Seoul/Tokyo

ROOM A

08:00-08:30

Satellite Symposium III (A). [Takeda]

Chair: Sang-We Kim (Univ. of Ulsan)

08:00-08:30

Translating Clinical Trial Experience to the Real World in ALK+ NSCLC ; Brigatinib

Sehhoon Park (Sungkyunkwan Univ.)

08:30-08:40

Break

08:40-09:40

Session V (A). Issues in Neoadjuvant Approach

Chair: Deog Gon Cho (The Catholic Univ. of Korea), Jin Hee Kim (Keimyung Univ.)

08:40-09:00

The Role of Neoadj CCRT for N2 NSCLC

Jae Myoung Noh (Sungkyunkwan Univ.)

09:00-09:20

Neoadjuvant Immunotherapy: Surgery Perspective

Jong Ho Cho (Sungkyunkwan Univ.)

09:20-09:40

Neoadjuvant Immunotherapy: Chemotherapy Perspective

Yuichiro Ohe (National Cancer Center Hospital, Japan)

09:40-09:50

Coffee Break

09:50-10:50

Session VI (A). Issues in Adjuvant Treatment

Chair: Dong-Wan Kim (Seoul National Univ.)

09:50-10:15

Adjuvant EGFR TKI in Non-Small Cell Lung Cancer

Ki Hyeong Lee (Chungbuk National Univ.)

10:15-10:40

Adjuvant Cytotoxic Chemotherapy in Elderly or Patients with Comorbidity

Hye Ryun Kim (Yonsei Univ.)

10:40-10:50

Discussion

11:05-11:45

Plenary Session

Chair: Jang Taewon (Kosin Univ.)

11:05-11:45

Immunotherapy in Advanced Non-Small Cell Lung Cancer: Current Status and Perspectives

Martin Reck (Lung Clinic Grosshansdorf Germany, Germany)

11:45-12:15

General Meeting

12:15-12:55

Luncheon Symposium II. [Yuhan]

Chair: Byoung Yong Shim (The Catholic Univ. of Korea)

12:15-12:55

Exploring the Prospects for 1L EGFR Mutant Non-Small Cell Lung Cancer; The Unveiling of Lazertinib’s Journey

Yun-Gyoo Lee (Sungkyunkwan Univ.)

12:55-13:10

Coffee Break

13:10-14:30

Session VII (A). ALK/KRAS/HER2/Other Targets

Chair: Takashi Seto (National Hospital Organization Kyushu Cancer Center, Japan), Jeong-Seon Ryu (Inha Univ.)

13:10-13:35

ROS1

Takashi Seto (National Hospital Organization Kyushu Cancer Center, Japan)

13:35-14:00

HER2 Mutation and Amplification

Jin Seok Ahn (Sungkyunkwan Univ.)

14:00-14:25

MET Mutation and Amplification

Ji-Youn Han (National Cancer Center)

14:25-14:30

Discussion

14:30-14:40

Coffee break

14:40-16:00

Overcoming Immuno-Oncology Resistance

Chair: James Chih Hsin Yang (National Taiwan Univ., Taiwan), Min Hee Hong (Yonsei Univ.)

14:40-15:05

Mechanisms of Primary Resistance to Anti-PD Therapy

Se-Hoon Lee (Sungkyunkwan Univ.)

15:05-15:30

Mechanisms of Acquired Resistance to Anti-PD Therapy

Daniel Shao Weng Tan (Duke NUS Medical School, Singapore)

15:30-15:55

Suggestion of Practical Strategies to Overcome Resistance

James Chih Hsin Yang (National Taiwan Univ., Taiwan)

15:55-16:00

Discussion

16:00-16:20

Closing & Awarding Ceremony

ROOM B

08:00-08:30

Satellite Symposium III (B). [Roche]

Chair: Ki Hyeong Lee (Chungbuk National Univ.)

08:00-08:30

Maintaining the Proven Standard in the First Line for ALK+ NSCLC

Jii Bum Lee(Yonsei Univ.)

08:30-08:40

Break

08:40-09:40

Session V (B). New Biomarkers in Lung Cancer

Chair: Ignacio I Wistuba (MD Anderson Cancer Center, USA), Wan-Seop Kim (Konkuk Univ.)

08:40-09:00

Rare Non-Small Cell Lung Cancer Tumors

Ignacio I Wistuba (MD Anderson Cancer Center, USA)

09:00-09:20

Role of TILs in Predicting Response to Immunotherapy

Hyojin Kim (Seoul National Univ.)

09:20-09:40

Major Pathologic Response after Neoadjuvant Therapy

William D. Travis (Memorial Sloan Kettering Cancer Center, USA)

09:40-09:50

Coffee Break

09:50-10:50

Session VI (B). Mesothelioma

Chair: Ji-Youn Han (National Cancer Center), Sukki Cho (Seoul National Univ.)

09:50-10:10

Novel Surgical Approaches in Malignant Pleural Mesothelioma

In Kyu Park (Seoul National Univ.)

10:10-10:30

Role of Perioperative Systemic Therapy for Malignant Pleural Mesothelioma

Tomoyuki Hishida (Keio Univ., Japan)

10:30-10:50

Targeted Therapy in Mesothelioma

Sook-hee Hong (The Catholic Univ. of Korea)

10:50-11:05

Break

11:05-11:45

Plenary Session

Chair: Jang Taewon (Kosin Univ.)

11:05-11:45

Immunotherapy in Advanced Non-Small Cell Lung Cancer: Current Status and Perspectives

Martin Reck (Lung Clinic Grosshansdorf Germany, Germany)

11:45-12:15

General Meeting

12:15-12:55

Luncheon Symposium II. [Yuhan]

Chair: Byoung Yong Shim (The Catholic Univ. of Korea)

12:15-12:55

Exploring the Prospects for 1L EGFR Mutant Non-Small Cell Lung Cancer; The Unveiling of Lazertinib’s Journey

Yun-Gyoo Lee (Sungkyunkwan Univ.)

12:55-13:10

Coffee break

13:10-14:30

Session VII (B). Surgery Updates

Chair: Famke Schneiders (Amsterdam Univ. Medical Centers, The Netherlands), Hyun Koo Kim (Korea Univ.)

13:10-13:30

Oncologic Unmet Needs and Needs to Know in Sublobar Resection

Hisashi Saji (St. Marianna Univ., Japan)

13:30-13:50

Trend of Lung Cancer Surgery: Nationwide Data

Dohun Kim (Chungbuk National Univ.)

13:50-14:10

Stereotactic Radiotherapy (SABR) for Early-Stage Non-Small Cell Lung Carcinoma: Clinical Applications and Immunological Insights

Famke Schneiders (Amsterdam Univ. Medical Centers, The Netherlands)

14:10-14:30

Role of Robotic Surgery in the Era of Sublobar Resection

Chang Hyun Kang (Seoul National Univ.)

14:30-14:40

Coffee break

14:40-16:00

Session VIII (B). Supportive Care in Lung Cancer

Chair: Jae Y. Kim (City of Hope, USA), Sung-Yong Lee (Korea Univ.)

14:40-15:05

Pulmonary Rehabilitation for Patients with Lung Cancer

Sei Won Lee (Univ. of Ulsan)

15:05-15:30

Comprehensive Geriatric Assessment in Lung Cancer Patients

Jae Y. Kim (City of Hope, USA)

15:30-15:55

Multidisciplinary Team Approach in Patients with Lung Cancer Bone Metastasis

Chai Hong Rim (Korea Univ.)

15:55-16:00

Discussion

ROOM C

08:00-08:30

Satellite Symposium III (C). [Boryung]

Chair: Eun Kyung Cho (Gachon Univ.)

08:00-08:30

Lurbinectedin in SCLC: From Clinical Trials to Real World Evidence

Min Hee Hong (Yonsei Univ.)

08:30-08:40

Break

08:40-09:10

Session V (C). Guidelines for Lung Cancer Treatment (*K)

Chair: Young Chul Kim (Chonnam National Univ.)

08:40-09:10

Development and Status of Lung Cancer Treatment Guidelines

Ho Joong Kim (Sungkyunkwan Univ.)

09:40-09:50

Break

9:50-10:50

Session VI (C). Oral Presentation II

Chair: Chan Kwon Park (The Catholic Univ. of Korea), Samina Park (Seoul National Univ.)

09:50-10:00

The Predictive Value of Early Tumor Response During Concurrent Chemoradiotherapy in Patients with Unresectable Stage III Non-Small Cell Lung Cancer

Hye In Lee (Univ. of Ulsan)

10:00-10:10

Neoadjuvant Lazertinib Therapy for Potentially Resectable EGFR-Mutated NSCLC Detected by EV-Based BALF Liquid Biopsy : Interim Analysis

In Ae Kim (Konkuk Univ.)

10:10-10:20

Real-World Data on Resected Stage II-IIIA EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) between 2015 and 2019

Junho Lee (Sungkyunkwan Univ.)

10:20-10:30

Comparison of Surveillance with Contrast Chest CT and Non-Contrast Chest CT in Patients who Survived 2 Years after Curative Resection for Lung Cancer

Bubse Na (Seoul National Univ.)

10:30-10:40

Implementation of CES-IMRT in Locally Advanced NSCLC Patients and the Outcomes of Esophageal Toxicity and Intra-thoracic Failure Pattern

Haesol Lim (Sungkyunkwan Univ.)

10:40-10:50

Simultaneous Visualization of Tumor and Intersegmental Plane during Pulmonary Segmentectomy by Intravenous Injection of Indocyanine Green

Kyungsu Kim (Korea Univ.)

10:50-11:05

Break

11:05-11:45

Plenary Session

Chair: Jang Taewon (Kosin Univ.)

11:05-11:45

Immunotherapy in Advanced Non-Small Cell Lung Cancer: Current Status and Perspectives

Martin Reck (Lung Clinic Grosshansdorf Germany, Germany)

11:45-12:15

General Meeting

12:15-12:55

Luncheon Symposium II. [Yuhan]

Chair: Byoung Yong Shim (The Catholic Univ. of Korea)

12:15-12:55

Exploring the Prospects for 1L EGFR Mutant Non-Small Cell Lung Cancer; The Unveiling of Lazertinib’s Journey

Yungyoo Lee (Sungkyunkwan Univ.)

12:55-13:10

Coffee break

13:10-14:30

Session VII (C). JLCS-KALC Joint Symposium: Management of Oligometastasis in the Era of Molecular Targeted Therapy and Immunotherapy: Recent Advances and Future Perspectives

Chair: Yoshihisa Shimada (Tokyo Medical Univ., Japan), Dae Ho Lee (Univ. of Ulsan)

13:10-13:30

Thoracic Surgical Oncology

Yoshihisa Shimada (Tokyo Medical Univ., Japan)

13:30-13:50

Recent Advances of Radiotherapy for Oligometastatic Lung Cancer

Yang-Gun Suh (National Cancer Center)

13:50-14:10

Establishing Multidisciplinary Treatment Strategies for Oligometastatic Disease and Oligo-Progressive Disease in Non-Small Cell Lung Cancer

Taichi Miyawaki (Juntendo Univ., Japan)

14:10-14:30

Medical Oncology

Jang Ho Cho (The Catholic Univ. of Korea)

14:30-14:40

Coffee break

14:40-16:00

Session VIII (C). Oral Presentation III

Chair: Yeol Kim (National Cancer Center), Changhoon Song (Seoul National Univ.)

14:40-14:50

Prognostic Implications of YAP1 Expression in Molecular Subtypes of Small Cell Lung Cancer

Gyeong-Won Lee (Gyeongsang National Univ.)

14:50-15:00

Gefitinib Maintenance after Definitive CCRT in EGFR Stage III NSCLC: Single Arm, Open Label, Multicenter phase 2 Pilot Trial

Yoonsil Jang (Univ. of Ulsan)

15:00-15:10

Tepotinib in Asian Patients with MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) in Long-Term Follow-Up from VISION

Ji-Youn Han (National Cancer Center)

15:10-15:20

A Phase 3, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients with EGFR or ALK Mutated in Non-Small Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

Sehhoon Park (Sungkyunkwan Univ.)

15:20-15:30

Tepotinib + Osimertinib in EGFR-Mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis

Tae Min Kim (Seoul National Univ.)

15:30-15:40

A Phase 2, Multicenter, Single Arm Study to Evaluate the Efficacy of Lazertinib in Patients with NSCLC who Harboring EGFR T790M Mutation Detected by BALF Liquid Biopsy: Interim Analysis

Heejoung Kim (Konkuk Univ.)

15:40-15:50

Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study

Taeyun Kim (Sungkyunkwan Univ.)

15:50-16:00

Local Ablative Therapy Combined with Pembrolizumab in Patients with Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Recursive Partitioning Analysis

Hye In Lee (Univ. of Ulsan)

ROOM D

13:10-14:30

Session VII (D). Joint Symposium with Korean Oncology Nursing Society: Comprehensive Review of the Treatment and Nursing Care in Lung Cancer (*K)

Chair: Eunyoung E. Suh (Seoul National Univ.), Eun Joo Kang (Korea Univ.)

13:10-13:35

Understanding of the Entire Treatment Course for Lung Cancer

Eun Joo Kang (Korea Univ.)

13:35-14:00

Nursing Interventions of Respiratory Symptoms in Lung Cancer

Seung Yun Lee (Asan Medical Center)

14:00-14:25

Comprehensive Oncology Nursing for the Patients with Metastases

Mi Sun Yi (Samsung Medical Center)

14:25-14:30

Discussion